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ORIGINAL ARTICLE
Introduction: The radiation doses used to treat unresectable 
lung cancer are often limited by the proximity of normal tissues. 
Overexpression of c-Met, a receptor tyrosine kinase, occurs in about 
half of non–small-cell lung cancers (NSCLCs) and has been associ-
ated with resistance to radiation therapy and poor patient survival. 
We hypothesized that inhibiting c-Met would increase the sensitivity 
of NSCLC cells to radiation, enhancing the therapeutic ratio, which 
may potentially translate into improved local control.
Methods: We tested the radiosensitivity of two high-c-Met–express-
ing NSCLC lines, EBC-1 and H1993, and two low-c-Met–express-
ing lines, A549 and H460, with and without the small-molecule 
c-Met inhibitor MK-8033. Proliferation and protein expression were 
measured with clonogenic survival assays and Western blotting, 
respectively. -H2AX levels were evaluated by immunofluorescence 
staining.
Results: MK-8033 radiosensitized the high-c-Met–expressing EBC-1 
and H1993 cells but not the low-c-Met–expressing cell lines A549 
and H460. However, irradiation of A549 and H460 cells increased 
the expression of c-Met protein at 30 minutes after the irradiation. 
Subsequent targeting of this up-regulated c-Met by using MK-8033 
followed by a second radiation dose reduced the clonogenic survival 
of both A549 and H460 cells. MK-8033 reduced the levels of radia-
tion-induced phosphorylated (activated) c-Met in A549 cells.
Conclusions: These results suggest that inhibition of c-Met could 
be an effective strategy to radiosensitize NSCLC tumors with high 
basal c-Met expression or tumors that acquired resistance to radia-
tion because of up-regulation of c-Met.
Key Words: NSCLC, c-Met, Radiosensitivity.
(J Thorac Oncol. 2012;7: 1211–1217)
Despite advances in diagnosis and treatment over the past several years, unresectable lung cancer remains a 
highly lethal disease, with a 5-year survival rate of only about 
14% to 15% among patients selected for combined-modality 
treatment in clinical trials.1 However, a larger percentage of 
patients with unresectable disease who are unable to tolerate 
combined-modality treatment, often receive either radiation 
or chemotherapy alone, and subsequently do even worse.2,3 
Although trials such as RTOG 9410 have demonstrated the 
benefits of concurrent external-beam radiation chemotherapy, 
we are often limited by its toxicity to the surrounding nor-
mal structures, particularly normal lung and esophagus.3,4 
Recently, receptor tyrosine kinases have been implicated in 
malignant progression and have become attractive targets for 
new therapeutics. Among them, c-Met, a hepatocyte growth 
factor receptor (HGF), has been of great interest as many solid 
malignancies, including lung cancers, express high levels of 
c-Met that are associated with therapy resistance.
HGF, the only known ligand for c-Met, is a 
multifunctional heterodimeric protein typically produced by 
mesenchymal cells. Its pleiotropic activities are mediated 
through its cellular receptor c-Met, a transmembrane tyrosine 
kinase encoded by the proto-oncogene mesenchymal-epithelial 
transition factor (MET). HGF and c-Met are overexpressed 
in a broad spectrum of human solid tumors including lung, 
breast, and brain.5,6 Activation of the HGF/c-Met pathway has 
been shown to confer protection against cell death induced by 
a variety of DNA-damaging agents, including radiation and 
topoisomerase inhibitors, both in vitro and in vivo.7,8 HGF 
has also been shown to function as an autocrine or paracrine 
growth factor.9 The c-Met pathway activates a program of cell 
dissociation and motility coupled with increased protease 
production that has been shown to promote cellular invasion 
through extracellular matrices in a process that closely 
resembles tumor metastasis in vivo.6
In patients with non–small-cell lung cancer (NSCLC), 
activation of the HGF/c-Met axis has been associated with 
poor survival.10 Amplification of c-Met has also been impli-
cated in resistance to therapies targeting the epidermal growth 
factor receptor (EGFR).11 Combining the inhibition of both 
EGFR and c-Met is being explored to overcome this putative 
resistance feedback loop. This strategy was tested in a recent 
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phase II study comparing the EGFR tyrosine kinase inhibitor 
erlotinib (Tarceva) plus placebo versus erlotinib plus a mono-
clonal antibody with c-Met for the treatment of NSCLC.12 
The study found improvement in the progression-free survival 
among patients with high c-Met expression (6.4 weeks versus 
12.4 weeks). The study also showed that 50%  of NSCLCs 
expressed elevated levels of c-Met, as measured by immuno-
histochemical staining, and the data suggest an increase in 
overall survival (7.4 months versus 7.7 months) with the addi-
tion of Met antibody for patients with high c-Met expression 
tumors.12
The goal of the study reported here was to test whether 
inhibition of the HGF/c-Met axis with the small-molecule 
inhibitor MK-8033 is effective for sensitizing NSCLC cells 
to radiation. We further tested whether radiation influences 
c-Met expression as compensator stress response to cellular 
DNA damage.
MATERIALS AND METHODS
Cell Cultures
The human NSCLC lines H1993, A549, and H460 
were obtained from the American Type Culture Collection 
(Manassas, VA), and EBC-1 cells were purchased from 
Health Science Research Resources Bank (Japan Health 
Sciences Foundation, Tokyo, Japan). The four cell lines were 
comprised of  high c-MET expressing (H1993 and EBC-1) 
and low c-MET expressing (A549 and H460) cells. The cells 
were cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin at 
37°C in 5% carbon dioxide conditions. Cell lines were vali-
dated by MD Anderson’s Characterized Cell Line Core facil-
ity by short tandem repeat (STR) DNA fingerprinting using 
the AmpFlSTR Identifiler kit according to the manufac-
turer’s recommendations (#4322288; Applied Biosystems, 
Carlsbad, CA). The STR profiles were compared with known 
American Type Culture Collection fingerprints, to the Cell 
Line Integrated Molecular Authentication database  (version 
0.1.200808; http://bioinformatics.istge.it/clima/, Nucleic 
Acids Research 37:D925-D932 PMCID: PMC2686526), and 
to MD Anderson’s fingerprint database.
Treatment Conditions and Irradiation
The small-molecule c-Met inhibitor, MK-8033 (Merck 
Research Laboratory, Boston, MA) was dissolved in dimethyl 
sulfoxide (DMSO) and used at final concentrations rang-
ing from 0.1 to 10 μM. For clonogenic survival assay, cells 
were pretreated with MK-8033 for 1 hour before irradiation. 
Control cells were treated with equal volumes of DMSO. 
A Mark I 137Cs irradiator (JL Shepherd and Associates, San 
Fernando, CA) was used to irradiate the NSCLC cells at a 
dose rate of 3.5 Gy/min at room temperature.
Clonogenic Survival Assays
Clonogenic (colony-forming) survival assays were done 
as described previously.13 Briefly, the H460, A549, and H1993 
NSCLC cells were seeded in 60-mm dishes and allowed to 
stabilize overnight. The next day, the cells were treated with 
either vehicle control (DMSO) or 1 μM MK-8033 for 1 hour 
followed by irradiation to a dose of 0, 2, or 4 Gy. Cells were 
then counted, seeded in 60-mm dishes, and incubated for 12 
days to allow macroscopic colony formation. Colonies were 
fixed and stained for 5 minutes with 0.5% crystal violet 
(Sigma, St. Louis, MO) in methanol. The number of colonies 
formed in each treatment group was counted, with a cutoff 
of 50 viable cells per colony. Survival was calculated relative 
to that of unirradiated cells (survival = [plating efficiency of 
treated cells]/[plating efficiency of control cells] where plat-
ing efficiency = [number of colonies formed by treated cells]/ 
[number of colonies formed by untreated cells]).13 Because 
the EBC-1 cells did not form colonies on dishes, these cells 
were cultured in suspension by seeding them to ultralow 
attachment 6-well plates (#3471; Costar; Sigma, St. Louis, 
MO) in Dulbecco’s modified essential medium (#10-010-CV; 
Cell Gro; VWR, Sugar Land, TX) with 1:50 B27 (#17504-
0440; Invitrogen), 20 ng/ml beta fibroblast growth factor 
(#PHG0264; Invitrogen, Green Island, NY), and 20 ng/ml epi-
dermal growth factor (#PHG0314; Invitrogen).
To assess whether radiation could induce c-Met 
expression resulting in adaptive radioresistance and whether 
MK-8033 could revert the radiation sensitivity, we exposed 
low-c-MET–expressing cells to 4 Gy, and treated them with 
MK-8033 (10 μM) 2 hours later. One day after the first radia-
tion dose, the cells were irradiated again with either 0, 2, or 
4 Gy radiation and plated into 60-mm dishes and allowed to 
form colonies for 12 days as described previously.
Protein Extraction and Immunoblotting
Cells were seeded on 10-cm Petri dishes, allowed 
to stabilize for 24 hours, and then treated with MK-8033 
(0.1–10 μM) for 2 hours, after which they were rinsed in ice-
cold phosphate-buffered saline (PBS) three times and lysed 
in lysis buffer containing 50 mmol/L 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid  (pH 7.9), 0.4 mol/L 
NaCl, 1 mM ethylenediaminetetraacetic acid, 2 μg/ml 
leupeptin, 2 μg/ml aprotinin, 5 μg/ml benzamidine, 0.5 mM 
phenylmethylsulfonyl fluoride, and 1% NP40. Lysates were 
subjected to electrophoresis on 4% to 15% sodium dodecyl 
sulfate-polyacrylamide electrophoresis gels (Cat #161–1158; 
Bio-Rad, Hercules, CA), transferred to a polyvinylidene 
fluoride membrane, and blocked with 5% bovine serum 
albumin (BSA) in Tris-buffered saline-Tween 20 (0.05%, vol/
vol) for 1 hour at room temperature. The membrane was then 
incubated with primary antibody overnight at 4°C. Antibodies 
for c-Met (Cat #4560), p-c-Met (Cat #3121), pAKT (Cat4051), 
p-extracellular signal-regulated kinase 1/2 (pERK1/2) (Cat 
#2232), and -actin (Cat #4967) were purchased from Cell 
Signaling (Danvers, MA). After the overnight incubation, the 
membrane was incubated with the appropriate horseradish 
peroxidase–conjugated secondary antibody (diluted 1:2000; 
Amersham Biosciences) for 1 hour. The blots were developed 
by enhanced chemiluminescence (Amersham Biosciences).
To analyze the effect of MK-8033 on the radiation-
induced phosphorylated c-Met, cells were irradiated with 
4 Gy, incubated for 2 hours, and treated with MK-8033 (10 
μM). One day after first irradiation, the cells were irradiated 
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again with 4 Gy, incubated for 2 hours, and then harvested for 
protein extraction and immunoblotting.
Immunofluorescent Staining for -H2AX
For this assay, 200,000 cells were plated on coverslips, 
placed in a 35-mm dish, and allowed to attach overnight. Then 
cells were irradiated (4 Gy) and, 2 hours later, exposed to 10 
μM MK-8033 for 24 hours. After the incubation period, cells 
were again irradiated (4 Gy) and incubated for up to 6 hours. 
Then, the cells were fixed with 1% paraformaldehyde for 10 
minutes, followed by ethanol (70%) fixation for 10 minutes at 
room temperature. The cells were then treated with 0.1% NP40 
in PBS for 20 minutes, washed in PBS four times, and then 
blocked with 5% BSA in PBS for 30 minutes. The cells were 
then incubated with anti–-H2AX (Millipore) antibody in 5% 
BSA in PBS overnight. The next day, the cells were incubated 
with fluorescein-isothiocyanate–labeled secondary antibody at 
a dilution of 1:300 (-H2AX) in 5% BSA in PBS for 30 min-
utes. Cells then were incubated in the dark with 4 4´,6-diamid-
ino-2-phenylindole, dihydrochloride (1 mg/ml) in PBS for 
5 minutes, and coverslips were mounted on a slide with an 
antifade solution (Molecular Probes; Invitrogen). Slides were 
examined using a Leica fluorescence microscope (Leica, 
Buffalo Grove, IL), and images were captured by a charge cou-
pled device camera and imported into Advanced Spot Image 
analysis software package. For each treatment condition, the 
number of  -H2AX foci were determined in at least 50 cells.14
RESULTS
MK-8033 Affected c-Met–Induced Signaling in 
High-c-Met–Expressing EBC-1 and H1993 Cells 
The activation of c-Met leads to cellular processes that 
are mediated in part by the extracellular signal-regulated 
kinase and Akt pathways. These pathways are known to be up-
regulated in various cancers, and have been shown to promote 
cellular proliferation and antiapoptosis. As shown in Figure 1, 
treating the high-c-Met–expressing EBC-1 and H1993 cells 
with 0.1 to 10 μM MK-8033 for 2 hours reduced the phos-
phorylation of c-Met, extracellular signal-regulated kinase, 
and Akt in a dose-dependent manner. However, this drug did 
not affect these signaling pathways in low-c-Met–expressing 
A549 or H460 cells (Fig. 1).
c-Met Levels Predicted Radiosensitizing Effect 
of MK-8033
Next, in analyzing the radiosensitizing effects of 
MK-8033, we found that treating the high-c-Met–express-
ing EBC-1 and H1993 cells with MK-8033 (1 μM) for 1 hour 
before irradiation sensitized these cells to radiation. However, 
this effect was not observed in the low-c-Met–expressing 
A549 and H460 cells (Fig. 2).
Radiation Induced c-Met Expression in Low-
c-Met–Expressing A549 and H460 Cells, and 
Sensitized Them to MK-8033
Next, we explored the effects of radiation on the induc-
tion or activation of c-Met in the low-c-Met–expressing 
NSCLC cells, A549 and H460. A one-time exposure to 4 Gy 
of radiation led to time-dependent increases in c-Met levels 
starting at 30 minutes and continuing for more than 24 hours 
in A549 cells, but not in H460 cells (Fig. 3A and B). However, 
we also found that adding MK-8033 (10 μM) 2 hours after 
the first irradiation (4 Gy) and exposing the cells to a second 
dose of radiation reduced their colony-forming ability rela-
tive to two radiation exposures without the drug in both cell 
lines, more potently, in H460 cells (Fig. 3C and D). Hence, 
at least in A549 cells, the up-regulation of c-Met made the 
cancer cells susceptible to MK-8033-induced radiosensitiza-
tion. Last, the combination of radiation followed by MK-8033 
followed by a second irradiation reduced the levels of p-c-Met 
in A549 cells relative to two doses of radiation alone (Fig. 4A). 
FIGURE 1. MK-8033 affects c-Met–induced signaling in EBC-1 and H1993 cells but not in A549 and H460 cells. MK-8033 
down-regulated the phosphorylation of c-Met, ERK, and Akt in EBC-1 and H1993 cells (cells with high basal c-Met levels) but 
not in A549 and H460 cells (cells with low-c-Met expression). ERK, extracellular signal-regulated kinase.
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Induction of c-Met seemed to be dose dependent and most 
prominent between 6 to 8 Gy (data not shown).
c-Met Inhibition Prolonged the Presence of 
Nuclear -H2AX Foci Induced by Irradiation
To determine the effect of c-Met inhibition on the DNA 
damage/repair kinetics after irradiation, we analyzed the pres-
ence of nuclear -H2AX foci after two fractions of irradiation 
in the absence or presence of MK-8033, as mentioned earlier, 
in A549 cells. We found that treatment with MK-8033 between 
fractionated irradiation increases the number of -H2AX for 
up to 6 hours compared with cells not treated with the drug 
(Fig. 4B and C), suggesting the MK-8033 interfered with the 
DNA-repair kinetics.
DISCUSSION
Because  there is a limitation on the dose of radiation 
that can be delivered to the malignant tissue or organ with-
out affecting the surrounding normal tissues, efforts are made 
to increase the sensitivity of cancer cells to radiation. In this 
study, we analyzed whether inhibition of c-Met activation 
would radiosensitize NSCLC cells. We found that inhibit-
ing c-Met with MK-8033 can effectively sensitize cell lines 
that constitutively express high c-Met levels to radiation but 
not in cell lines with low constitutive c-Met expression. We 
also observed up-regulation of c-Met protein after exposure 
to radiation, perhaps as a compensatory cellular-stresses 
response. This radiation-induced c-Met expression could be 
blocked using MK-8033, resulting in enhanced cell kill when 
combined with radiation. Our study suggests that the com-
bination of c-Met inhibitor and radiation should be further 
tested to confirm its clinical relevance.
The utilization of various kinase inhibitors in 
combination with radiation has also shown promise in the 
treatment of various forms of cancer, including lung cancer. 
Most such work has been done with EGFR inhibitors such 
as cetuximab and erlotinib. Erlotinib is currently approved 
by the U.S. Food and Drug Administration for refractory 
NSCLC, and may soon be approved as first-line therapy 
for NSCLC that has mutations in EGFR.15 EGFR has been 
shown to radiosensitize a variety of cancer cells in vitro and 
in animal models16 and in clinical settings in the treatment of 
FIGURE 2. MK-8033 radiosensitizes EBC-1 and H1993 cells but not A549 and H460 NSCLC cells. A 1-hour pretreatment with 
MK-8033 (1 µM) radiosensitized NSCLC cells with high basal c-Met levels (EBC-1 and H1993) but not in low c-Met-expressing 
cells. NSCLC, non–small-cell lung cancer.
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head and neck cancers, where the addition of cetuximab to 
radiation increased the median survival time from 29 months 
with radiation alone to 49 months.17 This strategy has been 
evaluated for NSCLC in RTOG 0324, in which cetuximab 
was combined with radiation for unresectable disease; the 
encouraging median survival time of 22.7 months from 
this combination compares favorably with RTOG 9410, in 
which the median survival time was 17 months. However, 
in Southwest Oncology Group S0023, the addition of 
EGFR tyrosine kinase inhibitor (gefitinib) post concurrent 
chemoradiation in unselected NSCLC patients negatively 
affected patient survival (35 months for placebo versus 
23 months for genifitinib).18 Increase in toxicity because 
of gefitinib could be responsible for decreased survival; 
however, the authors suggest that a 2% increase in toxicity 
fails to explain the statistically significant difference in the 
survival. Another important factor could be the patient’s 
smoking, EGFR, and K-ras status, which may predict 
response to EGFR tyrosine kinase inhibitor therapy.18,19
One of the mechanisms underlying the resistance of 
cancer cells to EGFR inhibitors was recently shown to involve 
c-Met amplification.20 Thus c-Met inhibition may even have 
a greater role when used in combination with EGFR inhibi-
tion. The converse, that resistance to c-Met inhibition can 
be mediated through up-regulation of EGFR, has also been 
demonstrated.21 Last, given the ability of c-Met kinase to drive 
the epithelial-to-mesenchymal transition, which is thought to 
encourage tumor-cell invasion and metastatic spread, blocking 
c-Met may not only benefit local control through improved 
radiosensitization, but could also help in preventing systemic 
spread of the disease.22–24
Previously, De Bacco et al.25 observed that radiation 
induces c-Met levels in breast cancer cells. The increase 
in c-Met and its activation could be responsible for the 
increased migratory and invasive potential of the can-
cer cells after irradiation.25 It would be interesting to see 
how irradiation affects c-Met levels in normal tissues and 
whether blocking this might potentially reduce radiation 
sensitization in these tissues as well. Studies to further 
investigate this should be carried out before combining 
c-Met inhibitor and radiation in clinical settings. If the 
phenomenon is observed in all the tissues, c-Met inhibition 
may also sensitize normal tissues to radiation. It would be 
also interesting to see whether induction of c-Met by radia-
tion is also observed in c-Met–mutated NSCLCs, which 
represent 2% to 4% of all cases.
In terms of the next steps to be taken, we are in the 
process of assessing the up-regulation of c-Met in serum 
samples from patients being treated for unresectable 
NSCLC. If serum c-Met levels prove to be a useful 
biomarker of resistance, then, that would provide a 
relatively noninvasive way of identifying the patients who 
would most likely benefit from c-Met inhibition. Serum 
c-Met levels may also prove to be useful in evaluating both 
the response to c-Met-targeting agents and the induction of 
c-Met by radiation.
FIGURE 3. Radiation induces c-Met expression and radiosensitizes A549 and H460 cells. Treatment of A549 and H460 cells 
with a single dose of 4 Gy radiation induced c-Met expression starting 30 minutes after the irradiation and persisting for 24 
hours (A and B). Furthermore, adding MK-8033 to fractionated radiation (4 Gy × two separated by 24 hours) reduced colony-
forming ability, suggesting that up-regulation of c-Met by the first irradiation further sensitized the cells to MK-8033.
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In conclusion, our findings suggest that c-Met inhibi-
tion may be an effective form of radiosensitization for the 
roughly 50% of NSCLC tumors with elevated basal levels of 
c-Met protein expression. Other NSCLC tumors that express 
low levels of c-Met may show up-regulation of c-Met after 
radiation therapy and may perhaps respond to c-Met inhibi-
tion as well. Given the emerging role of EGFR inhibitors in 
combination with radiation therapy for the treatment of lung 
cancer and the implication of c-Met in resistance to EGFR 
inhibitors, c-Met inhibitors are effective agents for overcom-
ing resistance to radiation therapy and resistance arising from 
other molecular feedback loops.
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